Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution
- 21 November 2017
- journal article
- research article
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 59 (8), 1920-1926
- https://doi.org/10.1080/10428194.2017.1403026
Abstract
Immunoparesis and polyclonal immunoglobulin recovery have been recently described as common indicators of immune dysfunction in patients with multiple myeloma. In the present study, we aimed to assess the impact of immunoparesis and polyclonal immunoglobulin recovery at day-100 post autologous stem cell transplant (auto-SCT) on clinical outcomes. A total of 302 patients were included for the analysis of immunoparesis, and 197 were evaluable for polyclonal immunoglobulin recovery evaluation. Immunoparesis was observed in 93.5% of cases, with 47% of cases having polyclonal immunoglobulin recovery at 12 months post auto-SCT. Median overall and progression-free survival were longer in the group of patients with complete or partial normalization of polyclonal immunoglobulins. Patients receiving consolidation had a lower level of polyclonal reconstitution. In conclusion, polyclonal immunoglobulin recovery by 12 months post-auto-SCT is associated with superior overall and progression free survival in patients with MM. Efforts to better enhance polyclonal recovery deserve further investigation.Keywords
This publication has 17 references indexed in Scilit:
- Immunologic approaches for the treatment of multiple myelomaCancer Treatment Reviews, 2017
- Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myelomaHaematologica, 2017
- Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myelomaLeukemia, 2014
- Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institutionHaematologica, 2013
- Monoclonal gammopathy of undetermined significance and risk of infections: a population-based studyHaematologica, 2011
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myelomaLeukemia, 2009
- International uniform response criteria for multiple myelomaLeukemia, 2006
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- B‐lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B‐cell progenitors and plasma cell precursorsBritish Journal of Haematology, 1998
- Phenotypic difference of normal plasma cells from mature myeloma cellsBlood, 1993